Rab Interacting Lysosomal Protein Protein

Rab Interacting Lysosomal Protein Protein

Introduction

Rab Interacting Lysosomal Protein Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@cantalupo2001]
<div class="infobox-header">Rab Interacting Lysosomal Protein (RILP)</div> [@jordens2001]
<div class="infobox-content"> [@hu2019]
<table> [@xu2021]
<tr><th>Protein Name</th><td>Rab Interacting Lysosomal Protein</td></tr> [@mcgough2014]
<tr><th>Gene</th><td>[RILP](/genes/rilp)</td></tr> [@wang2018]
<tr><th>UniProt ID</th><td>[Q8IVF2](https://www.uniprot.org/uniprotkb/Q8IVF2/entry)</td></tr> [@zhang2022]
<tr><th>Molecular Weight</th><td>48 kDa</td></tr>
<tr><th>Subcellular Localization</th><td>Lysosomes, Late Endosomes</td></tr>
<tr><th>Protein Family</th><td>RILP family</td></tr>
<tr><th>Associated Diseases</th><td>Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, Lysosomal Storage Disorders</td></tr>
</table>
</div>
</div>

Overview

The Rab Interacting Lysosomal Protein (RILP) is a key effector of Rab7 that regulates late endosomal and lysosomal trafficking. RILP serves as a molecular adaptor linking Rab7-positive organelles to the dynein-dynactin motor complex, facilitating retrograde transport of lysosomes and autophagosomes. This protein plays critical roles in autophagic clearance, cellular homeostasis, and neuronal survival, making it relevant to neurodegenerative disease pathogenesis.

Structure

Rab Interacting Lysosomal Protein Protein

Introduction

Rab Interacting Lysosomal Protein Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@cantalupo2001]
<div class="infobox-header">Rab Interacting Lysosomal Protein (RILP)</div> [@jordens2001]
<div class="infobox-content"> [@hu2019]
<table> [@xu2021]
<tr><th>Protein Name</th><td>Rab Interacting Lysosomal Protein</td></tr> [@mcgough2014]
<tr><th>Gene</th><td>[RILP](/genes/rilp)</td></tr> [@wang2018]
<tr><th>UniProt ID</th><td>[Q8IVF2](https://www.uniprot.org/uniprotkb/Q8IVF2/entry)</td></tr> [@zhang2022]
<tr><th>Molecular Weight</th><td>48 kDa</td></tr>
<tr><th>Subcellular Localization</th><td>Lysosomes, Late Endosomes</td></tr>
<tr><th>Protein Family</th><td>RILP family</td></tr>
<tr><th>Associated Diseases</th><td>Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, Lysosomal Storage Disorders</td></tr>
</table>
</div>
</div>

Overview

The Rab Interacting Lysosomal Protein (RILP) is a key effector of Rab7 that regulates late endosomal and lysosomal trafficking. RILP serves as a molecular adaptor linking Rab7-positive organelles to the dynein-dynactin motor complex, facilitating retrograde transport of lysosomes and autophagosomes. This protein plays critical roles in autophagic clearance, cellular homeostasis, and neuronal survival, making it relevant to neurodegenerative disease pathogenesis.

Structure

RILP contains several functional domains:

N-Terminal Domain (1-150 aa)

• Rab-binding region: Interacts with active GTP-bound Rab7
• Dimerization interface: Facilitates RILP homodimer formation

Central Domain (150-300 aa)

• Coiled-coil motifs: Mediates protein-protein interactions
• Dynein-dynactin recruitment site: Binds dynein light intermediate chain

C-Terminal Domain (300-400 aa)

• Dimerization domain: Stabilizes RILP dimers
• Regulatory region: Contains phosphorylation sites

Key Structural Features

Normal Function

Lysosomal Trafficking

RILP is essential for late endosome and lysosome transport:

Autophagy Regulation

RILP modulates autophagic flux:

Cellular Homeostasis

• Maintains lysosomal distribution
• Regulates endosomal maturation
• Controls nutrient sensing through mTORC1 signaling

Role in Neurodegeneration

Parkinson's Disease

RILP is strongly implicated in PD pathogenesis:

• LRRK2 Interaction: Phosphorylated by LRRK2 kinase (G2019S mutation increases activity)
• [α-Synuclein](/proteins/alpha-synuclein) Clearance: Impaired autophagic clearance of Lewy body components
• Dopaminergic Neuron Vulnerability: Reduced RILP expression in PD substantia nigra
• Mitochondrial Quality Control: Mitophagy defects contribute to neuronal death
• Therapeutic Target: LRRK2 inhibitors may normalize RILP function

Alzheimer's Disease

RILP dysfunction affects AD progression:

• Amyloid Clearance: [Autophagy](/entities/autophagy)-lysosomal pathway critical for [Aβ](/proteins/amyloid-beta) degradation
• Lysosomal Dysfunction: Impaired lysosomal transport in AD [neurons](/entities/neurons)
• [Tau](/proteins/tau) Pathology: May affect [tau](/proteins/tau) aggregate clearance
• Neuronal Survival: Lysosomal dysfunction contributes to synaptic loss

Huntington's Disease

RILP involvement in HD:

• Mutant [Huntingtin](/proteins/huntingtin-protein) Clearance: Autophagy-dependent clearance impaired
• Vesicular Transport: Defects in axonal transport contribute to neurodegeneration
• Therapeutic Potential: Enhancing RILP function may improve mutant [HTT](/genes/htt) clearance

Lysosomal Storage Disorders

• NPC Disease: RILP-mediated transport disrupted
• Gaucher Disease: Autophagy defects similar to PD

Signaling Pathways

LRRK2-RILP Axis

Autophagy-Lysosomal Pathway

Dynein-Dynactin Recruitment

Therapeutic Approaches

Small Molecule Modulators

• LRRK2 Inhibitors: May normalize RILP phosphorylation (GQ, MLi-2)
• Autophagy Enhancers: Boost RILP-mediated clearance
• Dynein Modulators: Enhance transport efficiency

Gene Therapy

• AAV-mediated RILP overexpression
• CRISPR-based RILP activation
• LRRK2 kinase-dead constructs

Protein-Protein Interaction Inhibitors

• Rab7-RILP interaction blockers
• Dynein-RILP disruptors

Biomarkers

RILP as a biomarker:

• Expression Levels: Altered in PD/AD brain and CSF
• Phosphorylation Status: p-RILP indicates LRRK2 activity
• Genetic Variants: RILP polymorphisms modify PD risk

Animal Models

Knockout Studies

• RILP null: Embryonic lethal (lysosomal transport defects)
• Conditional knockout: Neurodegeneration phenotype

Transgenic Models

• LRRK2 G2019S: RILP hyperphosphorylation
• α-Synuclein overexpression: RILP downregulation

Background

The study of Rab Interacting Lysosomal Protein Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• RILP Gene
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Huntington's Disease](/diseases/huntingtons-disease)
• [LRRK2 Gene](/genes/lrrk2)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-pathology)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)
• Lysosomal Trafficking